These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 11858843)

  • 1. Synthesis and cholinesterase activity of phenylcarbamates related to Rivastigmine, a therapeutic agent for Alzheimer's disease.
    Mustazza C; Borioni A; Del Giudice MR; Gatta F; Ferretti R; Meneguz A; Volpe MT; Lorenzini P
    Eur J Med Chem; 2002 Feb; 37(2):91-109. PubMed ID: 11858843
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Surprising discovery with Alzheimer's medication.
    Thacker PD
    Drug Discov Today; 2003 May; 8(9):379-80. PubMed ID: 12706648
    [No Abstract]   [Full Text] [Related]  

  • 3. Peripheral and dual binding site acetylcholinesterase inhibitors: implications in treatment of Alzheimer's disease.
    Castro A; Martinez A
    Mini Rev Med Chem; 2001 Sep; 1(3):267-72. PubMed ID: 12369973
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regional effects of donepezil and rivastigmine on cortical acetylcholinesterase activity in Alzheimer's disease.
    Kaasinen V; Någren K; Järvenpää T; Roivainen A; Yu M; Oikonen V; Kurki T; Rinne JO
    J Clin Psychopharmacol; 2002 Dec; 22(6):615-20. PubMed ID: 12454562
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lead optimization studies towards the discovery of novel carbamates as potent AChE inhibitors for the potential treatment of Alzheimer's disease.
    Roy KK; Tota S; Tripathi T; Chander S; Nath C; Saxena AK
    Bioorg Med Chem; 2012 Nov; 20(21):6313-20. PubMed ID: 23026084
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibitory effect of orally administered donepezil hydrochloride (E2020), a novel treatment for Alzheimer's disease, on cholinesterase activity in rats.
    Kosasa T; Kuriya Y; Matsui K; Yamanishi Y
    Eur J Pharmacol; 2000 Feb; 389(2-3):173-9. PubMed ID: 10688981
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of inhibitory activities of donepezil and other cholinesterase inhibitors on acetylcholinesterase and butyrylcholinesterase in vitro.
    Ogura H; Kosasa T; Kuriya Y; Yamanishi Y
    Methods Find Exp Clin Pharmacol; 2000 Oct; 22(8):609-13. PubMed ID: 11256231
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The new cholinesterase inhibitors for Alzheimer's disease, Part 2: illustrating their mechanisms of action.
    Stahl SM
    J Clin Psychiatry; 2000 Nov; 61(11):813-4. PubMed ID: 11105732
    [No Abstract]   [Full Text] [Related]  

  • 9. New insights into genetics and pathophysiology of Alzheimer's disease: what are the clinical and therapeutic implications?
    J Clin Psychiatry; 2000 Apr; 61(4):307-15. PubMed ID: 10830158
    [No Abstract]   [Full Text] [Related]  

  • 10. Risk of antipsychotic drug use in patients with Alzheimer's disease treated with rivastigmine.
    Suh DC; Arcona S; Thomas SK; Powers C; Rabinowicz AL; Shin H; Mirski D
    Drugs Aging; 2004; 21(6):395-403. PubMed ID: 15084141
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Rivastigmine, a new-generation cholinesterase inhibitor for the treatment of Alzheimer's disease.
    Jann MW
    Pharmacotherapy; 2000 Jan; 20(1):1-12. PubMed ID: 10641971
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of acetyl- and butyryl-cholinesterase in the cerebrospinal fluid of patients with Alzheimer's disease by rivastigmine: correlation with cognitive benefit.
    Giacobini E; Spiegel R; Enz A; Veroff AE; Cutler NR
    J Neural Transm (Vienna); 2002 Jul; 109(7-8):1053-65. PubMed ID: 12111443
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cholinesterase inhibitors in Alzheimer's disease: donepezil or rivastigmine?
    Sharma JC
    Int J Clin Pract; 2002; 56(6):414-5. PubMed ID: 12166537
    [No Abstract]   [Full Text] [Related]  

  • 14. Advances in the treatment of Alzheimer's disease: benefits of dual cholinesterase inhibition.
    Ballard CG
    Eur Neurol; 2002; 47(1):64-70. PubMed ID: 11803198
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical pharmacology of rivastigmine: a new-generation acetylcholinesterase inhibitor for the treatment of Alzheimer's disease.
    Polinsky RJ
    Clin Ther; 1998; 20(4):634-47. PubMed ID: 9737824
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FDA approves new cholinesterase inhibitor for Alzheimer's disease.
    Am J Health Syst Pharm; 2000 Jun; 57(11):1026, 1028. PubMed ID: 10876742
    [No Abstract]   [Full Text] [Related]  

  • 17. Lack of adverse pharmacodynamic drug interactions with rivastigmine and twenty-two classes of medications.
    Grossberg GT; Stahelin HB; Messina JC; Anand R; Veach J
    Int J Geriatr Psychiatry; 2000 Mar; 15(3):242-7. PubMed ID: 10713582
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Alzheimer disease. Pseudo-irreversible AChE inhibition with rivastigmine].
    Med Monatsschr Pharm; 1998 Aug; 21(8):248-9. PubMed ID: 9758554
    [No Abstract]   [Full Text] [Related]  

  • 19. Effectiveness of rivastigmine in Alzheimer's disease. Improvements in functional ability remain unestablished.
    Bentham P; Gray R; Sellwood E; Raftery J
    BMJ; 1999 Sep; 319(7210):640-1. PubMed ID: 10473490
    [No Abstract]   [Full Text] [Related]  

  • 20. Strategies for continued successful treatment of Alzheimer's disease: switching cholinesterase inhibitors.
    Gauthier S; Emre M; Farlow MR; Bullock R; Grossberg GT; Potkin SG
    Curr Med Res Opin; 2003; 19(8):707-14. PubMed ID: 14687441
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.